| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Aisha Walker | Q81292230 |
| Solomon F Ofori-Acquah | Q43124117 | ||
| Amma Twumwa Owusu-Ansah | Q57862405 | ||
| P2093 | author name string | Chibueze A Ihunnah | |
| P2860 | cites work | Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice | Q77719701 |
| In vitro antisickling activity of cromolyn sodium | Q77787284 | ||
| Transgenic sickle mice have vascular inflammation | Q78835117 | ||
| Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration | Q79771601 | ||
| Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation | Q79974524 | ||
| Lung function and airway hyperresponsiveness in adult patients with sickle cell disease | Q80112440 | ||
| Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation | Q81585139 | ||
| The role of mast cells in migraine pathophysiology | Q81860470 | ||
| Pulmonary complications of sickle cell disease | Q82667326 | ||
| Mast cells and inflammation | Q83029950 | ||
| Glucocorticoid treatment skews human monocyte differentiation into a hemoglobin-clearance phenotype with enhanced heme-iron recycling and antioxidant capacity | Q84806018 | ||
| Increased concentrations of IL-18 and uric acid in sickle cell anemia: contribution of hemolysis, endothelial activation and the inflammasome | Q84838678 | ||
| Brief Report: Plasma Concentrations of Hemopexin, Haptoglobin and Heme in Patients with Various Hemolytic Diseases | Q100802916 | ||
| The inflammasomes | Q24304087 | ||
| Development, migration, and survival of mast cells | Q24549674 | ||
| Adenosine receptors as therapeutic targets | Q24632095 | ||
| The NLR gene family: a standard nomenclature | Q24645445 | ||
| Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling | Q24655020 | ||
| Leukotrienes in pulmonary arterial hypertension | Q26853496 | ||
| The role of adenosine signaling in sickle cell therapeutics | Q27010098 | ||
| Neutrophil extracellular traps kill bacteria | Q27860996 | ||
| Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage | Q28214799 | ||
| Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma | Q28266003 | ||
| The biology of NKT cells | Q28277482 | ||
| New NO donors with antithrombotic and vasodilating activities, Part 28. N-(1-cyanoalkyl)-N-hydroxyureas | Q28370509 | ||
| Targeting caspase-1 by inhalation-therapy: effects of Ac-YVAD-CHO on IL-1 beta, IL-18 and downstream proinflammatory parameters as detected in rat endotoxaemia | Q28567849 | ||
| Adenosine receptors as drug targets--what are the challenges? | Q29346491 | ||
| Shared principles in NF-kappaB signaling | Q29547234 | ||
| Activation and regulation of the inflammasomes | Q29615664 | ||
| The inflammasome NLRs in immunity, inflammation, and associated diseases | Q29616025 | ||
| Inflammasomes in health and disease | Q29616356 | ||
| NF-kappaB: a key role in inflammatory diseases | Q29617726 | ||
| Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney | Q30304269 | ||
| Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease | Q30429393 | ||
| NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines | Q30435470 | ||
| Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction | Q30437433 | ||
| Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes | Q30441945 | ||
| Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation | Q30442067 | ||
| NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury | Q30443445 | ||
| Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury | Q30444009 | ||
| Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages | Q37304848 | ||
| Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies | Q37370659 | ||
| Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease | Q37489028 | ||
| FLAP inhibitors for the treatment of inflammatory diseases | Q37624502 | ||
| Asthma and sickle cell disease: two distinct diseases or part of the same process? | Q37653137 | ||
| Not simply misshapen red cells: multimolecular and cellular events in sickle vaso-occlusion | Q37680003 | ||
| Factors associated with survival in a contemporary adult sickle cell disease cohort | Q37705175 | ||
| Canakinumab for treatment of cryopyrin-associated periodic syndrome | Q37800938 | ||
| A single NFκB system for both canonical and non-canonical signaling | Q37811890 | ||
| CXCR3 ligands: redundant, collaborative and antagonistic functions | Q37827339 | ||
| Current status of inflammasome blockers as anti-inflammatory drugs | Q38011774 | ||
| Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis | Q38115527 | ||
| Systemic corticosteroids in acute chest syndrome: friend or foe? | Q38165525 | ||
| Hemoglobin s polymerization and red cell membrane changes | Q38192784 | ||
| Inflammatory mediators of endothelial injury in sickle cell disease | Q38192790 | ||
| Mast cell progenitors: origin, development and migration to tissues | Q38193606 | ||
| Regulation of NF-κB by TNF family cytokines | Q38222709 | ||
| Cytokine expression and signaling in drug-induced cellular senescence. | Q39791621 | ||
| Hemolysis in sickle cell disease | Q39939182 | ||
| Protease activity of plasma hemopexin | Q40398270 | ||
| Nitric oxide inhibits IgE-dependent cytokine production and Fos and Jun activation in mast cells | Q40489329 | ||
| The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP). | Q40630693 | ||
| Erythroid DAMPs drive inflammation in SCD. | Q40650786 | ||
| Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation | Q40798733 | ||
| Airway hyperreactivity in children with sickle cell disease | Q40885154 | ||
| Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. | Q40895215 | ||
| Leukotrienes in the pathogenesis of asthma | Q41355232 | ||
| Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition | Q41609000 | ||
| Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology | Q41614701 | ||
| 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. | Q42280189 | ||
| Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease | Q42517151 | ||
| Eicosanoids in sickle cell disease: potential relevance of neutrophil leukotriene B4 to disease pathophysiology. | Q42519406 | ||
| Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. | Q42523837 | ||
| Selective inhibition of l kappaB alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds | Q42548057 | ||
| Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. | Q42587651 | ||
| Mast cell activation contributes to sickle cell pathobiology and pain in mice | Q42612548 | ||
| The rat c-kit ligand, stem cell factor, induces c-kit receptor-dependent mouse mast cell activation in vivo. Evidence that signaling through the c-kit receptor can induce expression of cellular function | Q42768479 | ||
| Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT₂ and CysLT₁ receptors | Q42876825 | ||
| A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis | Q43012266 | ||
| Redox reactions of hemoglobin: mechanisms of toxicity and control | Q43182719 | ||
| Targeting leukotriene B4 in inflammation | Q43464822 | ||
| Modulation of endothelial cell activation in sickle cell disease: a pilot study | Q43550991 | ||
| Activated polymorphonuclear cells increase sickle red blood cell retention in lung: role of phospholipids | Q43826638 | ||
| NF-κB is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors | Q37215741 | ||
| Extracellular hemin crisis triggers acute chest syndrome in sickle mice | Q37259191 | ||
| Acute chest syndrome in adults with sickle cell disease | Q73783522 | ||
| Circulating activated endothelial cells in sickle cell anemia | Q73884398 | ||
| Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group | Q73911088 | ||
| Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism | Q74083183 | ||
| Comparative oxidation of hemoglobins A and S | Q74477846 | ||
| Nuclear factor kappa B: important transcription factor and therapeutic target | Q77587561 | ||
| Elevated IL-8 levels during sickle cell crisis | Q77689840 | ||
| Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion | Q30445346 | ||
| Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members | Q30459060 | ||
| Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm | Q30476171 | ||
| Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin | Q30506249 | ||
| Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo | Q30561804 | ||
| Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction. | Q30757538 | ||
| Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease | Q30945205 | ||
| In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology | Q33398661 | ||
| Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling | Q33694628 | ||
| Oxygen regulates the band 3-ankyrin bridge in the human erythrocyte membrane | Q33726914 | ||
| Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease | Q33749670 | ||
| Nuclear factor-kappa B (NFkappaB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease | Q33761124 | ||
| Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis | Q33768693 | ||
| NKT-cell subsets: promoters and protectors in inflammatory liver disease | Q33862229 | ||
| The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up | Q33890227 | ||
| The noncanonical NF-κB pathway | Q34031207 | ||
| LTB4 is a signal-relay molecule during neutrophil chemotaxis | Q34077159 | ||
| Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin. | Q34101137 | ||
| Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease | Q34158521 | ||
| Protease-activated receptors in inflammation, neuronal signaling and pain | Q34175474 | ||
| Central nervous system mast cells in peripheral inflammatory nociception | Q34189684 | ||
| Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and Inflammation | Q34254403 | ||
| Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia | Q34308407 | ||
| Hemolysis-induced lethality involves inflammasome activation by heme | Q34314447 | ||
| Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels | Q34337258 | ||
| Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice | Q34350304 | ||
| FcεR1-mediated mast cell reactivity is amplified through prolonged Toll-like receptor-ligand treatment | Q34391700 | ||
| The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease | Q34409133 | ||
| Transcellular biosynthesis of eicosanoid lipid mediators | Q34438393 | ||
| Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. | Q34476932 | ||
| Mast cell activation syndrome as a significant comorbidity in sickle cell disease | Q34564293 | ||
| Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. | Q34570825 | ||
| Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin | Q34750520 | ||
| Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events | Q34750534 | ||
| Sickle erythrocytes and platelets augment lung leukotriene synthesis with downregulation of anti-inflammatory proteins: relevance in the pathology of the acute chest syndrome | Q34782494 | ||
| Blood viscosity and the expression of inflammatory and adhesion markers in homozygous sickle cell disease subjects with chronic leg ulcers | Q34901902 | ||
| Inflammasomes | Q34931052 | ||
| A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases | Q35044923 | ||
| The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression | Q35200339 | ||
| Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias | Q35222193 | ||
| Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease | Q35230235 | ||
| NF-κB in immunobiology. | Q35348282 | ||
| A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. | Q35350543 | ||
| Asthma in children with sickle cell disease and its association with acute chest syndrome. | Q35537558 | ||
| Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell | Q35666145 | ||
| The Association of Cytokine Levels With Cognitive Function in Children With Sickle Cell Disease and Normal MRI Studies of the Brain | Q35739099 | ||
| FcepsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells | Q35849299 | ||
| Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease | Q36012888 | ||
| Mast cells in the development of adaptive immune responses | Q36015885 | ||
| Mast cell degranulation activates a pain pathway underlying migraine headache | Q36098310 | ||
| "Minor" hemoglobinopathies: a risk factor for asthma | Q36177317 | ||
| Leukocyte adhesion and the pathophysiology of sickle cell disease | Q36327712 | ||
| Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease | Q36370871 | ||
| Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells | Q36407169 | ||
| Potential effector and immunoregulatory functions of mast cells in mucosal immunity | Q36539857 | ||
| Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson | Q36797240 | ||
| Detrimental effects of adenosine signaling in sickle cell disease | Q36818005 | ||
| Neurobiological mechanisms of pain in sickle cell disease | Q36831700 | ||
| Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies | Q36870257 | ||
| Headache in children with sickle cell disease: prevalence and associated factors | Q36882504 | ||
| CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system | Q36898124 | ||
| Gene-centric association study of acute chest syndrome and painful crisis in sickle cell disease patients | Q37026772 | ||
| Elevated urinary leukotriene E4 levels are associated with hospitalization for pain in children with sickle cell disease | Q37059538 | ||
| Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease | Q37082000 | ||
| Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease | Q37100903 | ||
| Antagonistic regulation by the transcription factors C/EBPα and MITF specifies basophil and mast cell fates | Q37127767 | ||
| 5-Lipoxygenase: mechanisms of regulation | Q37173201 | ||
| Iron nitrosyl hemoglobin formation from the reactions of hemoglobin and hydroxyurea | Q43883526 | ||
| Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease | Q43883731 | ||
| Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. | Q43977840 | ||
| Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases | Q44496573 | ||
| Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway | Q44756903 | ||
| Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients | Q44765672 | ||
| Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice | Q44786816 | ||
| Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. | Q44805631 | ||
| Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy | Q44929555 | ||
| Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases | Q45816370 | ||
| Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease | Q46085894 | ||
| CXCR3+CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury | Q46141630 | ||
| Urinary cysteinyl leukotriene E(4) is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease | Q46172921 | ||
| The interaction between oxidative stress and mast cell activation plays a role in acute lung injuries induced by intestinal ischemia-reperfusion | Q46255702 | ||
| Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease | Q46343143 | ||
| Differential effects of hydroxyurea and zileuton on interleukin-13 secretion by activated murine spleen cells: implication on the expression of vascular cell adhesion molecule-1 and vasoocclusion in sickle cell anemia | Q46520590 | ||
| Adenosine-dependent activation of hypoxia-inducible factor-1 induces late preconditioning in liver cells | Q46572514 | ||
| Effect of adenosine A2A receptor agonist (CGS) on ischemia/reperfusion injury in isolated rat liver | Q46693986 | ||
| Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium | Q46907147 | ||
| Cutting edge: the ontogeny and function of Va14Ja18 natural T lymphocytes require signal processing by protein kinase C theta and NF-kappa B. | Q47810582 | ||
| Propofol prevents lung injury after intestinal ischemia-reperfusion by inhibiting the interaction between mast cell activation and oxidative stress | Q47864252 | ||
| Clinical response of patients with sickle cell anemia to cromolyn sodium nasal spray. | Q50723169 | ||
| Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells. | Q50734042 | ||
| Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. | Q50776572 | ||
| The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. | Q50790934 | ||
| Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. | Q50860898 | ||
| Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion. | Q51106899 | ||
| CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. | Q53565669 | ||
| Periapical cytokine expression in sickle cell disease. | Q53641131 | ||
| Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. | Q53670384 | ||
| Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. | Q54549073 | ||
| Asthma in sickle cell disease. | Q55043575 | ||
| Mortality in sickle cell disease. Life expectancy and risk factors for early death. | Q55065788 | ||
| Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. | Q55230640 | ||
| Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase | Q57779720 | ||
| Mass Spectral Analysis of Asymmetric Hemoglobin Hybrids: Demonstration of Hb FS (α2γβS) in Sickle Cell Disease | Q58463707 | ||
| Quaternary Structure Regulates Hemin Dissociation from Human Hemoglobin | Q59599936 | ||
| Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients | Q61713371 | ||
| Hemopexin-dependent heme uptake via endocytosis regulates the Bach1 transcription repressor and heme oxygenase gene activation | Q62746880 | ||
| Role of hybrid tetramer formation in gelation of haemoglobin S | Q66961118 | ||
| The stability of the heme-globin linkage in some normal, mutant, and chemically modified hemoglobins | Q67669448 | ||
| Autoxidation of hemoglobin enhanced by dissociation into dimers | Q67803009 | ||
| Hemopexin metabolism in patients with altered serum levels | Q71073072 | ||
| Serum interleukin-6 levels in the steady state of sickle cell disease | Q71364127 | ||
| The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease | Q71632332 | ||
| High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease | Q72241034 | ||
| Antisickling activity of sodium cromoglicate in sickle-cell disease | Q73171663 | ||
| Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo | Q73258433 | ||
| P433 | issue | 1 | |
| P921 | main subject | sickle-cell disease | Q185034 |
| P304 | page(s) | 281-297 | |
| P577 | publication date | 2015-07-11 | |
| P1433 | published in | Translational Research | Q15761127 |
| P1476 | title | Inflammatory targets of therapy in sickle cell disease | |
| P478 | volume | 167 |
| Q57159913 | A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study |
| Q40582651 | A trial of unrelated donor marrow transplantation for children with severe sickle cell disease |
| Q52316849 | Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease. |
| Q47569224 | Clinical and genetic factors are associated with pain and hospitalisation rates in sickle cell anaemia in Cameroon |
| Q90436085 | Effect of Gum Arabic (Acacia senegal) on C-reactive protein level among sickle cell anemia patients |
| Q92622979 | Emerging disease-modifying therapies for sickle cell disease |
| Q37729403 | Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help? |
| Q91727985 | Influence of sickle cell disease on susceptibility to HIV infection |
| Q37715448 | Lectin-like oxidized low-density lipoprotein receptor (LOX-1) in sickle cell disease vasculopathy |
| Q59701095 | Modulating NRF2 in Disease: Timing Is Everything |
| Q90029430 | New insights into the pathophysiology and development of novel therapies for sickle cell disease |
| Q90429790 | OxInflammation: From Subclinical Condition to Pathological Biomarker |
| Q38859913 | Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial |
| Q90034851 | Updated mechanisms underlying sickle cell disease-associated pain |
Search more.